What is manogepix?

Manogepix, also known as MK-8507, is an experimental antiviral drug developed by Merck & Co. It is being investigated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in combination with other antiretroviral drugs.

Manogepix works by inhibiting the viral capsid protein, which is essential for the replication of HIV-1. It is believed to have a novel mechanism of action and may potentially be effective against drug-resistant strains of HIV-1.

In clinical trials, manogepix has demonstrated potent antiviral activity with a sustained viral load reduction without causing significant side effects. It has also shown activity against different HIV-1 subtypes, including those that are resistant to current antiretroviral therapies.

As of 2021, manogepix is still in the early stages of clinical development and has not been approved by any regulatory agency. However, it holds promise as a new treatment option for HIV-1 infection.